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Abstract: The porcine reproductive and respiratory syndrome virus (PRRSV), an RNA virus inducing
abortion in sows and respiratory disease in young pigs, is a leading infectious cause of economic
losses in the swine industry. Modified live vaccines (MLVs) help in controlling the disease, but their
efficacy is often compromised by the high genetic diversity of circulating viruses, leading to vaccine
escape variants in the field. In this study, we hypothesized that a DNA prime with naked plasmids
encoding PRRSV antigens containing conserved T-cell epitopes may improve the protection of MLV
against a heterologous challenge. Plasmids were delivered with surface electroporation or needle-free
jet injection and European strain-derived PRRSV antigens were targeted or not to the dendritic cell
receptor XCR1. Compared to MLV-alone, the DNA-MLV prime- boost regimen slightly improved the
IFNγ T-cell response, and substantially increased the antibody response against envelope motives
and the nucleoprotein N. The XCR1-targeting of N significantly improved the anti-N specific antibody
response. Despite this immuno-potentiation, the DNA-MLV regimen did not further decrease
the serum viral load or the nasal viral shedding of the challenge strain over MLV-alone. Finally,
the heterologous protection, achieved in absence of detectable effective neutralizing antibodies,
was not correlated to the measured antibody or to the IFNγ T-cell response. Therefore, immune
correlates of protection remain to be identified and represent an important gap of knowledge in
PRRSV vaccinology. This study importantly shows that a naked DNA prime immuno-potentiates
an MLV, more on the B than on the IFNγ T-cell response side, and has to be further improved to
reach cross-protection.
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1. Introduction
The Porcine Reproductive and Respiratory syndrome virus (PRRSV), a positive single stranded
RNA enveloped virus of the Arteriviridae family, is responsible for high economical losses in the swine
industry. The PRRSV induces reproductive failures during late gestation in sows and respiratory
disorders in neonates and in growing-finishing piglets, resulting in poor growth performance [1,2].
The PRRSV RNA genome includes 10 open reading frames (ORFs), which encode for seven structural
proteins and 14 nonstructural proteins. Two distinct genotypes, now considered as separate species [3],
exist which present only 60% genomic sequence identity, with PRRSV-1 being dominant in Europe
and PRRSV-2 in America. Both species co-exist in Asia with frequent emergence of highly pathogenic
strains. Among European strains, Eastern strains have emerged that display high virulence and
cause large outbreaks, whereas circulating Western strains generally display low virulence and more
insidious disease. The Eastern and Western strains are genetically divergent and grouped in subtypes 3
and 1 respectively [4]. This genetic diversity is related to the high dynamics of PRRSV genome, which
continuously and rapidly evolves, generating new variants and expanding its diversity which is the
main hurdle to effective prevention and control of PRRS through vaccination [4]. Modified live vaccines
(MLVs) obtained by serial in vitro passages for attenuation are currently the most used vaccines, as they
can reduce disease severity as well as the duration of viremia [5,6]. However, MLV efficacy is greater
against homologous strains and declines dramatically for genetically distant heterologous PRRSV
strains [5,6].
T cell-mediated immunity has been proposed to be involved in the heterologous protective
efficacy of MLVs against diverging strains [7]. Interestingly, T-cell epitopes from different PRRSV
ORFs have been described that are conserved through European distant strains [8]. In a parallel
study, in order to enhance and broaden the T-cell mediated immunity induced by MLVs, we used
a DNA-MLV prime-boost strategy with plasmids encoding PRRSV antigens (PRRSV-AG) including
conserved T-cell epitopes (NSP1β, RdRp, M-derived antigens) as well as the B cell immuno-dominant
nucleoprotein N from a recent Western European strain [9]. We found that the DNA prime broadened
the T-cell response and potently enhanced the anti-N IgG response induced by MLV. Furthermore,
when PRRSV-AGs were expressed in vaccibody (VB) platforms targeted to XCR1, a receptor selectively
expressed by a dendritic cell (DC) subset across species [10], the anti-N IgG response, but not the
IFNγ T-cell response, was further enhanced. In that first study, the plasmids were combined with
cationic poly-lactoglycolide acid (PLGA) nanoparticles (NPs) and administered intra-dermally with
surface electroporation (EP). NPs may affect the efficacy of the DNA-MLV prime-boost strategy and the
DC-targeting outcome, and they add complexity and cost to the manufacture step. In addition, surface
EP, although very efficient, has currently not yet been adapted to vaccine delivery in veterinary field
conditions. A painless intradermal jet delivery device has been shown to be particularly efficient to
induce high neutralizing antibody responses in pigs using DNA encoding the influenza hemagglutinin
antigen [11] and such a convenient delivery, now licensed for human use, could be adapted to field use
for veterinary applications. Therefore, in the present study, we evaluated the T and B cell responses
induced by a DNA-MLV prime-boost strategy with naked DNA vaccines administered using surface
EP compared to jet delivery and coding for PRRSV-AGs targeted or not to XCR1. We also assessed
whether such a DNA-MLV prime-boost strategy would enhance the cross-protection against a distant
European PRRSV strain.
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2. Material and Methods
2.1. Antibodies (Abs)
The anti-pig IFNγ mouse P2G10 mAb (capture), biotinylated anti-pig IFNγ P2G11 mAb and
alkaline phosphatase-conjugated streptavidin were from MabTech AB (Nacka Strand, Sweden).
The anti-mCherry rabbit IgG was purchased from Rockland, Tebu-bio SAS, Le Perray en Yvelines,
France). The Alexa Fluor 594-conjugated goat anti-rabbit IgG was from ThermoFisher Scientific,
Waltham, MA, USA.
2.2. Viruses
The PRRSV-1, subtype 1, 13V091 (FL13), and 07V063 (FL07) strains have been described
previously [12]. FL13 was attenuated by 73 in vitro passages in the MARC-145 cell line, clone F4,
kindly provided by Prof. Dr. M. Pensaert (UGent, Belgium). This attenuated strain, designated
here as MLV-FL13b, was unable to infect primary alveolar macrophages, even after in vivo passage
(unpublished). The FL07 strain was propagated on specific-pathogen-free alveolar macrophages.
2.3. DNA Vectors
An mCherry encoding plasmid (mCherry2-N1, here referred to as pmCherry) was obtained from
Addgene (Cambridge, MA, USA) under MTA. A firefly luciferase expression plasmid (pLuc) was
kindly provided by Stéphane Biacchesi (INRA, Jouy-en-Josas, France). The plasmid vectors encoding
untargeted PRRSV antigens (AG) are based on a pcDNA3.1 vector: pN, pNSP1β, and pRdRp vectors
encoded for the native N, NSP1β, and RdRp viral proteins respectively and pGP4GP5M encodes a
chimera that was derived from a previous publication [13] and transposed to the FL13 strain [14].
The construction of the vaccibody (VB) vaccine format has been previously described [15]; it includes
a targeting unit, a dimerization unit made of a human Ig hinge and CH3 sequences of human IgG3,
and an antigen unit. A VB with porcine XCL1 as the targeting unit was previously published by
our group [16] and this same targeting unit sequence including the natural XCL1 leader sequence
was used here. All sequences were codon-optimized according to the porcine species, synthesized
by GenScript (Piscataway, NJ, USA) and cloned in a pUMVC4a vector (Aldevron, Fargo, ND, USA).
The four VB plasmids encoding PRRSV AG are pXCL1-N, pXCL1-GP4GP5M, pXCL1-NSP1β1 (AA1 to
202 of NSP1β), and pXCL1-NSP1β2 (AA182 to 383 of NSP1β) and are further described in submitted
manuscript 1 [9]. The NSP1β sequence had to be separated into two parts to allow expression of
the chimera. Vaccibody constructs encoding for RdRp did not lead to detectable expression upon
transfection in HEK293 cells and therefore were not used [9]. Plasmid productions for immunization
were prepared using endotoxin-free NucleoBond® EF kit (Nagel Macherey GmbH, Düren, Germany)
according to the manufacturer’s instructions and were stored at −20 ◦C until use.
2.4. Pig Studies, Ethic and Authorizations
All experiments were conducted in accordance with the EU guidelines and the French regulations
(DIRECTIVE 2010/63/EU, 2010; Code rural, 2018; Décret #2013-118, 2013). All experimental procedures
were evaluated and approved by the Ministry of Higher Education and Research. The experiments
with the pLuc plasmid (skin cell transduction) were approved by the COMETHEA ethic committee
under the APAFIS notification number 2017120408328722 v2 (23 February 2018) in accordance with
national guidelines on animal use and performed at the Animal Genetics and Integrative Biology unit
(GABI-INRA), France, under the accreditation number for animal experimentation C78-719. Large White
pigs (10 weeks of age) were obtained from UEPR-INRA-Rennes-Saint Gilles. The immunization
experiments with PRRSV antigen-encoding plasmids was approved by the Comité d’Éthique en
Expérimentation Animale Val de Loire (CEEA VdL, committee #19) under the APAFIS notification
number 2015051418327338 v10 (3 July 2017) and were conducted at the Plateforme d’infection
Expérimentale PFIE-INRA, Nouzilly, France, (https://doi.org/10.15454/1.5535888072272498e12) under
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the accreditation number for animal experimentation D37-1753 and under A-BSL3 containment.
Social material enrichment (balls, chains) was provided to maintain piglet welfare. Large White pigs
(1 month of age) were obtained from the INRA conventional breeding unit Unité Expérimentale de
Physiologie Animale de l’Orfrasière PAO-INRA, Nouzilly, France, working under the A37-1754
accreditation number for animal experimentation. The piglet mothers were checked to be
PRRSV-seronegative with a commercial ELISA.
2.5. In Vivo Gene Transfer
Pigs were anesthetized (2% isofluorane) to avoid animal discomfort with electroporation (EP)
and to optimally control the quality of vaccine administration. Pig skin was cleaned with Vetedine®
soap (Vetoquinol, Magny Vernois, France), washed and dried. Part of the same experiment was
submitted to publication for a study comparing plain pLuc DNA administration to DNA on
cationic poly-lactoglycolide nanoparticles and patch administration [14]. Therefore, the values
of the luminescence and of IL1β and IL-8 secretion induced by EP delivery are the same ones as in that
paper. For EP delivery, intradermal injection of pLuc and pmCherry (100 µg in 100 µL saline) was done
in the inguinal zone and EP was performed on the site of injection using the CUY 21 EDIT system (NEPA
GENE Co. Ltd., Chiba, Japan). Disk electrodes (10 mm) were loaded with conductive gel (Alcyon, Paris,
France) and 6 electric pulses were applied during 10 ms with 90 ms interval. Trolamine 0.6% (Biafine,
Johnson & Johnson Santé Beauté, Issy-les-Moulineaux, France) was spread on the transfected zone
right after administration. For needle-free jet delivery intradermal application (Tropis ID, Pharmajet,
https://pharmajet.com/tropis-id/, Golden, CO, USA), pLuc and pmCherry (100 µg in 100 µL saline)
were administered in the lower thoracic zone. This method of administration is designated as PJ in this
study. After 24 h, pigs were euthanized and skin biopsies were collected using an 8-mm disposable
biopsy punch (Kai medical, Tokyo, Japan) after cleaning of the skin with Vetedine soap and Vetedine
10% solution (Vetoquinol, Magny-Vernois, France). Control skin was harvested from the same zone
(inguinal for the EP and thoracic zone PJ).
2.6. Detection of pLuc Expression
Two 8 mm-diameter biopsies transfected with pLuc per pig and per mode of delivery were cut
into small pieces and lysed with 150 µL of lysis reagent (Luciferase Assay System E1500, Promega,
Madison, WI, USA). Bioluminescence was measured per each biopsy using the In Vivo Imaging System
(IVIS-200, Xenogen, Caliper LifeSciences, Hopkinton, MA, USA) after adding 100 µl luciferin substrate.
A region of interest (ROI) was manually selected and the intensity of luminescence (photons/sec/cm2)
was recorded.
2.7. Detection of pmCherry Expression
One biopsy from skin transfected with pmCherry was collected per pig (3 pigs) and per mode of
delivery (EP and PJ) and fixed in buffered formalin 4%. Immunohistochemical staining and clearing
were performed following the iDISCO+ protocol [17]. Biopsies were incubated 7 days in each antibody
solutions. The primary antibody (anti-mCherry rabbit IgG) and the secondary antibody (Alexa Fluor
594-conjugated goat anti-rabbit) were diluted 1:500 in PBS. Before clearing, samples were counterstained
with 4′,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich, Merk KGaA, Darmstadt, Germany) diluted
at 5 µg/mL before clearing. Biopsies were mounted under coverslips (ThermoFisher Scientific, Waltham,
MA, USA) using spacers made with Picodent twinsil speed 22 dental paste (Picodent, Wipperfürth,
Germany) and sealed with Dentalon plus dental paste (Phymep, Paris, France). Images were acquired
with a Leica SP8 two-photon microscope using a HCX IRAPO L 25X/0,95NA water immersion objective
(Leica microsystems, Wetzlar, Germany). DAPI and Alexa Fluor 594 were both excited at 800 nm with
a Chameleon Vision II laser (Coherent, Lisse, France) and fluorescence was detected by NDD HyD
detectors (Leica microsystems, Wetzlar, Germany) with BP 525/50 and BP585/40 filters respectively.
Image analyses were performed using the Fiji software (ImageJ2, Madison, WI, USA).
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2.8. Detection of Inflammatory Cytokines in Pig Transfected Skin
For cytokine production assessment, two biopsies (8-mm diameter each) per pig and per
mode of delivery were carefully washed in PBS and each placed in 1 mL RPMI + 10% FCS +
1% antibiotic/antimycotic 100X cocktail (Gibco, ThermoFisher Scientific, Waltham, MA, USA) for
24 h. Concentrations of secreted cytokines were assessed by cytometric beads assay for simultaneous
detection of 12 swine cytokines (IL-4, IFNα, TNFα, IL-2, IL-8, IL-13, IL-12, IL-6, IFNγ, IL-10, IL-17,
IL-1β) as described [18].
2.9. Immunization of Pigs and Infectious Challenge
Pigs (1-month-old) were split into 8 groups including 8 or 9 piglets per group, respecting a balance
between males and females, and taking their parental origin so that genetic biases between groups were
minimal. The groups’ description and the immunization schedule are shown in Table 1. On day 0 (D0),
4 groups of pigs were anesthetized (2% isofluorane) and were injected with the DNA plasmids (400 µg
each), either with EP or with PJ, as described above. In the case of EP, DNA in 400 µL was injected in
3 spots and in the case of PJ, DNA in 400 µL was injected in the costal zone in 4 spots. Trolamine 0.6%
(Biafine®, Johnson & Johnson Santé Beauté, Issy-les-Moulineaux, France) was spread on the EP zone
administration. On D34, the 4 DNA-vaccinated groups and an additional MLV-only group received
MLV-FL13b (105.5 TCID per pig) intramuscularly in 2 mL PBS + Ca2+Mg2+. On D63, all pigs including
a control group were anesthetized with xylazine (Rompun®, Bayer SAS, Lyon, France) at 2 mg/kg and
ketamine (Imalgene®, Merial, Boehringer Ingelheim, Ingelheim am Rhein, Germany) at 10 mg/kg by
the intramuscular route and they received 2 × 105 TCID50 FL07 per pig by the intra-nasal route (1 mL
per nostril).
Table 1. Vaccination with DNA vectors, MLV-FL13b and infection with the FL07 heterologous
PRRSV strain.
Vaccines and
Dates
Groups
Ctrl 1 MLV-FL13b
DNA+MLV-FL13b
XCL1-EP XCL1-PJ UT-EP UT-PJ
DNA
D0
pXCL1-N 2
pXCL1-GP4GP5M
pXCL1-NSP1β1
pXCL1-NSP1β2
pRdRp
pXCL1-N
pXCL1-GP4GP5M
pXCL1-NSP1β1
pXCL1-NSP1β2
pRdRp
pN
pGP4GP5M
pNSP1β
pRdRp
pN
pGP4GP5M
pNSP1β
pRdRp
MLV-FL13b
D34 -
3 + 4 + + + +
FL07 challenge
D63 + + + + + +
1 non-vaccinated group, 2 plasmids per pig inoculated at D0, 3 not injected, 4 injected.
Appropriate equipment was used for the virus administration (protective cover-all clothing,
gloves, and safety shoes). Body temperature was monitored by sensor chips placed under superficial
skin muscle. Pigs were examined daily and monitored for dyspnea, coughing, nasal discharge,
conjunctivitis, ear color, diarrhea, activity. They were euthanized on D88 by an overdose of Dolethal®
(Vetoquinol, Magny Vernois, France, 50 mg/kg).
2.10. Nasal Swab and Serum Collections
Nasal swabs were collected for viral detection in 500 µL RPMI and for antibody detection in PBS +
cOmplete Protease Inhibitor Cocktail (Roche, Sigma-Aldrich, Merck, KGaA, Darmstadt, Germany),
and they were immediately frozen. For virus detection, nasal swabs were collected D58, 69, 71, 73, 76,
and 83. Sera were collected for antibody detection on D0, 34, 48, 58, 83, 88, and for viral detection on
D58, 69, 71, 73, 76, 83.
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2.11. Overlapping Peptides
Overlapping peptides (20 mers, offset 8) covering the NSP1β, RdRp, N and the GP4GP5M
PRRSV antigens were synthetized by Mimotopes (Mimotopes Pty Ltd., Victoria, Australia, http:
//www.mimotopes.com). Upon receipt, the peptides were diluted in H20:acetonitrile (50:50 vol) at
a 5 mg/mL concentration and grouped as pools of peptides not exceeding 50 peptides: pool N
(15 peptides), pool GP (GP4GP5M chimera, 40 peptides), pool NSP1β1 (47 peptides) and 2 pools RdRp1
(peptide 1 to 40), pool RdRp2 (peptide 41 to 80). A 20-mer peptide from the HIV polymerase was used
as control. The list of the peptides is provided in Supplementary Table S1.
2.12. IFNγ Detection by ELISPOTS
PBMCs were collected on D49 on three 8 ml Vacutainer® CPT™ (BD-Biosciences, San Jose, CA,
USA) by centrifugation at 1800× g for 35 min at 25 ◦C. PBMCs were washed with PBS + 1.3 mM
citrate and re-suspended in X-vivo medium (Ozyme, Saint-Cyr-l’Ecole, France) + 50% FCS + 1.3 mM
citrate and rested overnight. PBMCs were re-suspended in X-VIVO-20 medium supplemented with
2% FCS, 100 U/mL penicillin and 1 µg/mL streptomycin (culture medium) and counted for live cells.
IFNγ-secreting T cells were detected using polyvinylidene difluoride (PVDF) membrane-bottomed
96-well plates (MultiScreen®HTS, Millipore, Merck KGaA, Darmstadt, Germany) coated with 15 µg/mL
anti-porcine IFNγ (capture mAb) in PBS. PBMCs (2 × 105) were plated per well and were stimulated
with the different pools of overlapping peptides described above at a 10 µg/mL final concentration
for 18 h, in triplicates. An HIV polymerase-derived peptide and ConA at 25 µg/mL were used as
controls. After 18 h, the IFNγ-secreting cells were revealed by sequential incubations with 0.5 µg/mL
biotinylated anti-IFNγ followed by 0.5 µg/mL alkaline phosphatase conjugated-streptavidin (MabTech
AB, Nacka Strand, Sweden) and 1-StepTM BCIP/NBT reagent (Sigma, Merck KGaA, Darmstadt,
Germany). The spots were enumerated using the iSPOT reader from AID Autoimmun Diagnostica
GmbH (Straßberg, Germany). Positive wells were considered if the mean spot numbers in the
stimulated conditions were significantly superior to the spot numbers in the control peptide conditions
(p < 0.05, paired t-test) and if >55 spots. The mean number of spots from stimulated minus control
peptide wells was calculated.
2.13. Detection of Anti-N IgG and Anti-Envelope IgG
For the anti-N IgG detection, the sera prior challenge was assayed using the Ingezim PRRS 2.0 kit
(Ingenasa, Eurofins-technologies, Bruxelles, Belgium) at a 1:40 dilution. The S/P ratios were calculated
as follows: [OD sample minus OD negative control]: [OD positive control minus OD negative control],
using the mean of the experimental negative controls (non-vaccinated group including 8 pigs, at each
considered time point). For the detection of anti-envelope IgG (ELISA-Env), 96-well-plates were coated
with PRRSV-1 envelope proteins. Individual pig sera (D58 and D88) were diluted 1:20 and incubated
on coated plates at RT for 1 h. The plates were subsequently incubated with peroxidase-labeled
anti-pig IgG antibody at 20 ◦C for 1 h. The peroxidase enzymatic activity was finally revealed using
tetramethylbenzidine (TMB) substrate (ThermoFischer Scientific). OD was measured at 450 nm using
a TECAN microplate reader Tecan Group Ltd., Männedorf, Switzerland. S/P ratios were calculated as
for anti-N Abs.
2.14. Detection of Neutralizing Antibodies (NAbs)
NAbs were quantified in sera on MARC-145 cells against the FL13b vaccine strain according to
the Virus Neutralization Titer (VNT) method described in a previous paper [19].
2.15. Viral Detection by Specific qRT-PCR
For quantification of viral RNA in sera and nasal swab, viral RNA was first extracted from
100 µL biological fluid using NucleoSpin® RNA Virus kit from Nagel-Macherey GmbH, Düren,
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Germany. A one-step qRT-PCR was performed using the iTaqTM universal probes One-Step kit
(BIO-RAD, Hercules, CA, USA). Primers were designed to amplify selectively FL07 and not FL13
sequences, in the ORF1 gene: forward primer 5′-TGGCACAGAATCCGACAACA-3′, reverse primer
5′- GTCTAAGGCCTGCGCATCA-3′. A fluorescent probe was designed that hybridizes to the specific
FL07 PCR product: FAM 5′-AGCTCGCCTCTGACTT-3′ TAMRA. A standard curve was made with
four 10-fold dilutions of the FL07 inoculum (101 to 104 TCID50/mL), each spiked in control pig serum
and extracted with the NucleoSpin® RNA Virus kit. The qRT-PCR was performed with 2 µL of
sample elution in 10 µL final mix and the cycling involved the following steps: reverse transcription at
50 ◦C for 10 min, denaturation at 95 ◦C for 3 min, amplification 40 cycles at 95 ◦C for 15 s, and 60 ◦C
for 30 s. TaqMan run of experimental samples contained 2 replicates, mock pig serum RNA and
H20. The reactions were carried out in a CFX ConnectTM light cycler (BIO-RAD). The number of
TCID50-equivalent (TCID50 eq)/mL in each sample was determined using the FL07 RNA standard
calibration curve. For each animal, the area under the curve (AUC) of the TCID50eq per ml over 25 days
(viral RNA AUC) was calculated. The specificity of the qPCR reactions for FL07 and FL13 detection
was checked on the respective standard curves and strictly no heterologous virus could be detected.
2.16. Statistical and Correlation Analyses
Data were analyzed with the GraphPad Prism 7.0 software (San Diego, CA, USA). The unpaired
non-parametric two-way Mann–Whitney test was used to compare the inflammatory cytokine results,
the luciferase, the ELISPOT, the Ab results and the viral AUC between 2 groups. The principal
component analysis was done with 16 factors and included the individual viral RNA copies/mL at
D69, 73 and 83 as well as the viral RNA AUC, the individual body temperatures at D65, the T-cell
responses at D49 to the N, GP4GP5M, NSP1β, RdRp1 and RdRp2 pools, the total number of spots
per pig (with and without the NSP1β responses), the number of T-cell antigens recognized per pig,
the anti-N Ab at D58 and 83, and the anti-envelope Ab at D58 and D88. PCA graphics was produced
using the FactoMineR R package (http://factominer.free.fr/). The correlation analysis between the
different immune and viral parameters was done with a bilateral Spearman non-parametric test.
3. Results
3.1. Transduction Efficacy of Pig Skin Cells upon DNA Delivery with a Needle-Free High Pressure Jet Injection
(Pharmajet Tropis-ID device, PJ) Versus Surface EP
In order to deliver our DNA vaccines in a convenient, well-tolerated and efficient manner, we
compared the transduction efficacy of pig skin cells with a pLuc plasmid administered as plain DNA
via needle-free high pressure jet injection (PJ) versus surface EP. Skin biopsies were harvested 24 h after
pLuc delivery and processed for detection of luciferase expression by bioluminescence measurement.
Figure 1A shows that PJ delivery induced luciferase expression reaching higher values (2.69 × 109 ±
1.57 × 109 p/s/cm2/sr) than surface EP delivery (1.30 × 108 ± 1.46 × 107, p < 0.005).
In addition, we evaluated the in situ expression of a pmCherry plasmid, 24 h post-delivery with PJ
and EP, using a whole tissue clearing strategy and detection with 2-photon microscopy. Figure 2 shows
distinct mCherry-positive cells: keratinocytes (A, B), dermal cells resembling fibroblasts, cells with
branched projections suggestive of DCs (C, D), and cells resembling adipocytes (E, F). No clear
difference in the micro-anatomy of mCherry expression could be seen between EP and PJ delivery
from three skin samples per injection mode.
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C) Biopsies from the transfected sites (independent duplicates) were placed in culture medium for 24 
h. Secreted IL-1β (B) and IL-8 (C) from each biopsy (same symbols as in A) were measured with a 
cytometric bead assay multiplex assay and the mean is shown. Statistically significant differences 
between 2 groups were calculated using the Mann–Whitney non-parametric test, ** = p <0.01. 
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Figure 1. Expression of luciferase activity and cytokine secretion upon in vivo transfection of pig
skin cells with pLuc delivered using surface electroporation (EP) and Pharmajet Tropis-ID device (PJ).
Three Large White pigs (3-month-old, number 829, 850, and 910) were anesthetized. In the inguinal
zone, 100 µg pLuc was injected intradermally in 100 µL saline and the skin site was subjected to surface
EP as described in the Material and Methods. In the thoracic zone, 100 µg pLuc was administered
with PJ in 100 µL saline. After 24 h, 8-mm biopsies were harvested at the sites of administration.
(A) Biopsies from the transfected sites (independent duplicates) were processed for luciferase activity
detection. Co trol skin of the sa e respective sites (inguinal a lower thoracic) ere collected and
treat d in parallel and are desig ated as CTRL EP and CTRL PJ respectively. The luciferase activity
results (p/s/cm2/sr) of the transfected control skin from pig 829, 850, and 910 ar indicated by a
distinct symbol (ci cle, square, and triangle respectiv ly) and means are sh wn. (B,C) Biopsies from
th transfected sites (independent duplicates) were placed in culture medium for 24 h. Secreted IL-1β
(B) and IL-8 (C) from e ch biopsy (same symbols as in A) were measured with a cy ometric bead assay
multiplex assay and the mean is shown. Statistically ignificant differences betw en 2 groups were
alculated using the Mann–Whitney non-parametric test, ** = p < 0.01.
Skin biopsies were placed in flotation in culture medium for 24 h. The cytokine content was
analyzed in a multiplex assay for detection of IL-4, IFNα, TNFα, IL-2, IL-8, IL-13, IL-12, IL-6, IFNγ,
IL-10, IL-17, IL-1β. The DNA administration with PJ induc d variable and low levels of IL-1β and IL- 8
(n statistical significance versus control skin of the same site) whereas EP induced si n ficant amount
of both cytokines (Figure 1B). Th expression of IL-2, IFNγ, and IL-13 was not or in onsistently detected
and the expression of the other cytokines was not modulated upon DNA administration.
Altogether, PJ a pears mor potent than EP to transduce skin cells and induces lower inflammatory
responses than EP.
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3.2. IFNγ T-Cell Responses Induced by a Prime-Boost DNA-MLV-FL13b Strategy with DNA Encoding
PRRSV-AGs Targeted or Not to XCR1 and Delivered with EP or PJ
We showed in ref. [9] that an improvement of the T-cell response breadth was achieved by a
DNA-MLV prime-boost strategy, versus DNA-only or MLV-only. We selected DNA plasmids from
the ones that were used in that study (see Material and Method section). These plasmids encode
PRRSV-AGs containing T-cell epitopes, which are conserved through viral strains, i.e., RdRp, NSP1β
and M [8]. The M sequence is included in a GP4GP5M chimera previously used in the context of
DC- targeting [13] and the immuno-dominant B cell antigen N is also used to probe the antibody
response. The PRRSV-AGd are either targeted to XCR1 via VB platforms using pig XCL1 as a
targeting unit (pXCL1-GP4GP5M, pXCL1-N, pXCL1-NSP1β1, and pXCL1-NSP1β2) or untargeted
(UT, pGP4GP5M, pN, pNSP1β, pRdRp). The PRRSV-AG sequences were derived from the PRRSV-1
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13V091 strain (FL13, [12]). On day 0 (D0), plasmids encoding targeted or non-targeted PRRSV-AGs
were administered either with EP or PJ, according to Table 1. As a difference with ref. [9], the DNA
was not combined to cationic PLGA nanoparticles (see introduction). On D34, the attenuated FL13
MLV strain was administered by the intramuscular route. The IFNγ T-cell response to overlapping
peptides covering the different vaccine PRRSV-AGs was assayed using the ELISPOT technique from
PBMCs collected on D49 (i.e., D15 after the MLV-FL13b boost). The response against RdRp was
evaluated with two peptide pools (N and C-terminal), in order not to exceed 50 peptides per pool
and avoid toxicity. The MLV-FL13b and DNA+MLV-FL13b groups showed statistically significant
IFNγ T-cell responses above the unimmunized control group to the N, GP4GP5M and RdRp2 peptide
pools (Figure 3A–E). Few animals per group presented responses to the NSP1β peptide pools as
a difference to in our previous study where the response was higher [9]; the use of cationic PLGA
NPs (see the discussion) or difference in genetic make-up of the pigs between studies could explain
this discrepancy. Higher responses to N and RdRp2 peptide pools were obtained in the PJ group as
compared to in the MLV-FL13b group, with no clear benefit of DC-targeting (Figure 3A–E). The number
of peptide pools recognized per pig was calculated (Figure 3F). Whereas five out of nine pig PBMCs
responded to at least two peptide pools in the MLV-FL13b group, this proportion appears higher in the
DNA+MLV-FL13b groups, such as in the XCL1-PJ group (eight out of nine pigs, Figure 3F). However,
the increase over the MLV-FL13 group was not statistically significant for any of the DNA-MLV-FL13b
group. In conclusion of this experiment using naked DNA administered with surface EP or PJ, the T
cell response was slightly improved, but not significantly, by the DNA-MLV prime-boost strategy over
the MLV-FL13b alone.
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Figure 3. IFNγ T-cell responses induced by MLV-FL13b and DNA+MLV-FL13b. PBMCs were collected
on D49 and they were analyzed for IFNγ T-cell response upon re-stimulation with overlapping peptide
pools (10 µg/mL) in ELISPOT assays. (A–E) The responses to the N, GP4GP5M, NSP1β, RdRp1 (peptide
1 to 40) and RdRp2 (peptide 41 to 80) peptide pools are shown. An irrelevant peptide (10 µg/mL) was
used as control. The mean number of spots from triplicates of stimulated minus control wells are
shown (see Material and Methods). The mean number of spots across pigs per group is shown as a box.
The plasmids used to immunize each group are listed in Table 1. (F) The number of recognized peptide
pools per pig is reported (mean ± sem). Statistically-significant differences between 2 groups were
calculated using the Mann–Whitney non-parametric test. The letter a indicates significant differences
with the non-vaccinated control group, and b with the MLV-only group. Number 1 corresponds to
p < 0.05, 2 to p < 0.01, 3 to p < 0.001.
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3.3. Antibody Responses Induced by the Prime-Boost DNA-MLV-FL13b Strategy
The anti-N IgG response in the sera was measured using a commercial ELISA kit [20]. The anti-N
IgG response was already detected at the time of MLV injection, showing that a single DNA
administration with EP and PJ is efficient at inducing anti-N responses. As previously found in
ref. [9], the anti-N IgG response was clearly enhanced in the DNA+MLV-FL13b groups as compared to
in the MLV-FL13b-only (Figure 4, at least p < 0.05 in all comparisons and timing). A higher proportion
of pigs presented S/P ratios over 10 in the XCL1 groups than in the UT groups indicating that the
XCR1-targeting of N is beneficial to the anti-N IgG response (Figure 4, p < 0.01 at D58). Sera collected at
D58 were assayed for NAb detection using a classical in vitro neutralization assay with MARC-145 cells
and FL13b virus, as well as with an experimental ELISA with PRRSV envelope proteins (ELISA-Env,
PRRSV-1). None of the sera demonstrated neutralizing activity in our assay with MARC-145 cells.
However, as shown Figure 5, all DNA-MLV groups presented higher titers in the ELISA-Env assay
than the MLV-only group (p < 0.05). The discrepancy between the in vitro assay with MARC-145 and
the ELISA-Env assay may be explained by the higher sensitivity of the ELISA test. Notably the ELISA
titers were heterogeneous between pigs, possibly due to genetic differences in the antibody repertoires
between pigs. This finding indicates that the DNA priming favors the generation of antibodies directed
to antigenic determinants of the PRRSV-1 MLV envelope.
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Figure 4. Anti-N IgG responses induced by MLV-FL13b and DNA+MLV-FL13b. Sera were collected on
the indicated days and analyzed at a 1:40 dilution for anti-N IgG detection with the Ingezim PRRS 2.0
kit. The S/P ratios are reported and mean (box) is shown per group. Statistically significant differences
between 2 groups were calculated using the Mann–Whitney non-parametric test. The letter a indicates
significant differences with the non-vaccinated group, b with the MLV-only group, c with the respective
UT group. Number 1 corresponds to p < 0.05, 2 to p < 0.01, 3 to p < 0.001, 4 to 0.0001.
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Figure 5. Anti-Env IgG responses induced by MLV-FL13b and DNA+MLV-FL13b. Sera collected at
D58 were analyzed at a 1:20 dilution with the ELISA-Env. Statistically-significant differences between
2 groups were calculated using the Mann–Whitney non-parametric test. The letter a indicates significant
differences with the non-vaccinated group, b with the MLV-only group. Number 1 corresponds to
p < 0.05, 2 to p < 0.01. The p-value is indicated when close to significance.
3.4. Protection Induced by the Prime-Boost DNA-MLV-FL13b Strategy against a Heterologous Challenge
with FL07
So far, the increase of the immune responses induced by the DNA-MLV-FL13b strategy over the
MLV-FL13b-induced responses reflects immuno-potentiating properties, which might be beneficial
to cross-protection against a heterologous PRRSV-1 strain. FL13 shows a ig genetic divergence
to all, currently publicly available complete genomes of PRRSV-1 viruses and appears isolated in
the phylogenetic tree, in a distinct branch from the Flanders’ 07V063 strain (FL07) [12]. The mean
amino-acid conservation between the variable GP2, GP3, GP4, GP5 proteins of FL07 and FL13 is 84.9%,
which is a usual variation used to assess heterologous protection [21]. Pigs were challenged intra-nasally
ith FL07 on D63. The body temperature was m nitored with subcutaneous sensors. A slight rise
in temperature (◦C) from 38.3 ± 0.3 to 39.4 ± 0.4 (mean ± sem) was measured on D65 in the control
non-vaccinated group and this rise was delayed to D66 in the MLV group, to 39.4 ± 0.6 (Suppleme tary
Figure S1). The rise was lower in the DNA-MLV-FL13b groups, and especially in the PJ groups
(p < 0.05, Supplementary Figure S1G). The pigs did not present any pathological symptoms upon daily
monitoring. FL07 RNA was measured on D58, 69, 71, 73, 76, 83 in the sera and in the nasal secretions
sing a specific qRT-PCR assay which w s checked to be unable to detect FL13 (Suppleme tary
Figure S2 and Figure 6). The area under the curve (AUC) of viral FL07 RNA detection (TCID50eq/mL)
over time was calculated for each pig. MLV-FL13b significantly reduced the viral RNA content in serum
(542 ± 168) and nasal secretion (74± 124) compared to in the serum of non-vaccinated pigs (12810 ± 4624
and 1254 ± 1796, for serum and nasal secretion respectively). However, the DNA-MLV-FL13b regimen
did not enhance the protective effect of MLV-FL13b (Supplement ry Figure S2 and Figure 6). Th Ab
levels detected with the ELISA-Env were enhanced by FL07 inf ction at D88 versus D58 before infection
(compare Figure 5 and Supplementary Figure S3), indicating that FL07 infection further boost d the
Ab response against PRRSV-1 envelope determinants, without differences between vaccinated groups.
However effective NA s against FL13b in classical i vitro neutralization assay were ot detected
at D71 or D88, indicating that this FL13 DNA-MLV prime-boost strategy, followed by heterologous
challenge FL07 was not efficient at inducing neutralizing or cross-neutralizing Abs.
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Figure 6. Protection induced by MLV-FL13b and DNA+MLV-FL13b against a FL07 heterologous
challenge. The vaccinated pigs were subjected to FL07 challenge on D63 and the FL07 virus was
selectively detected in sera (A) and nasal swab fluids (B) with specific qRT-PCR on D58 (before
challenge), 69, 71, 73, 76, and 83. TCID50-equivalent/mL (TCID50eq/mL) was calculated with a viral
standard curve (see Material and Methods). The limit of detection for FL07 was calculated as being
0.2 TCID50eq/mL. The area under the curve (AUC) for each pig was calculated and the mean (box) ±
sem is shown per group. The letter a indicates significant differences with the non-vaccinated group
(non-parametric–Mann-Whitney). Number 1 corresponds to p < 0.05, 2 to p < 0.01, 3 to p < 0.001).
3.5. Lack of Immune Correlates of Protection Induced by the MLV and Prime-Boost DNA-MLV-FL13b
Strategies against the Heterologous FL07 Challeng
The MLV and DNA+MLV-vaccinated pigs demonstrate a variability in their B and T-cell immune
responses and in the viral shedding values which could be us ful to identif correlates of protection
against a heterologous chall nge. The ifferent immunological, body t mperature at D65 and viral
variables were loaded on a principal component analysis (PCA) in order to identify the main axes of the
data’s variance as well as corr lated variables. The Dim 1 axis, which explains 31.32% of th varianc ,
clearly separat s the dat betw en th control and the vaccinated groups (Figure 7A). The PCA loading
of each v riable shown in Figure 7B rev als tha the total IFNγ T-cell response contributes most
significantly to the Dim 1 axis, whereas the RNA viral data contribute most to the Dim 2 and little to
the Dim 1 axis. None of the measured i munological data clearly opposes the viral data, indicating
that IFNγ T-cell, an i-N and anti-env Ab responses are not correlates f heterologous viral rot ction,
which w s also confirmed by a Spearman analysis (2 by 2 analyses). The IFNγ T-cell response data
appear to oppose the hyperthermia d ta at D65, which contributes moderately to Dim 1, and these
variables significantly anti-correlat , although to a l w degr e (Spearman analysis, p = 0.01, r = −0.35).
The PCA loading of the experime tal data of the vacci ated groups only (excluding the contr ls)
provided the same conclusions. Overall the statistics analysis of the experimental data shows that the
level of hete logous prote tion, achieved in the absenc of d tectable NAb to the MLV vaccine, not
correlated to th m asured immune parameters, i.e., IFNγ T-c lls, anti-N and anti-env responses.
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Figure 7. Principal component analysis (PCA) of the experimental variables of the immunization and
the heterologous challenge. (A) PCA plot of the responses of pigs is depicted, with each pig represented
as a dot in a specific colour according to its group assignment (see legend). (B) the PCA loading of
each individual variable (16 factors) is shown and includes the individual viral RNA TCID50eq/mL at
D69 (V-D69), D73, and D83, the viral RNA AUC (V-AUC), the individual body temperatures at D65
(Temp-D65), the IFNγ T-cell responses at D49 to the N (IFNγ-N), GP4GP5M, NSP1β, RdRp1, and RdRp2
pools, the total number of spots per pig (IFNγ-all), the number of T-cell antigens recognized per pig
(AG/pig), the anti-N IgG at D58 (AbN-D58), and D83 and the anti- nvelope Ab t D58 (AbEnv-D58)
and D88. Dim 1 is the axis r presenting the highest percent of the variance and Dim 2 represents the
second one.
4. Discussion
In this work, we showed that a DNA-MLV-FL13b prime-boost strategy using naked DNA
administered with surface EP and PJ has a slight positive effect on the IFNγ T-cell response breadth and
enhances the anti-N and envelope IgG response magnitude over the ones induced by MLV- FL13b-only,
suggesting that the prime-boost strategy has an immuno-potentiation effect, especially on the B-cell
arm of the response. However, this vaccine strategy did not improve the viral protection against a
heterologous distant PRRSV strain over the one induced by MLV-FL13b alone.
In a parallel work [9], the DNA prime promoted more clearly the breadth of the T-cell response
induced by MLV-FL13b than in this present work. In that parallel study, the DNA was combined to
cationic PLGA NPs, which also promoted local inflammation (unpublished, [14]). We propose that
NPs combined to DNA has a positive adjuvant effect over naked DNA and that this adjuvant effect
was needed to optimize the T-cell response triggered by the DNA-MLV prime-boost strategy. However,
the precise mechanisms of the adjuvant effect of NPs, which might reside in an improved sensing of
the DNA, remain to be investigated.
Interestingly, naked DNA promoted the B-cell response induced by MLV-FL13b, whether the
DNA was administered with surface EP or with PJ. Importantly, PJ administration was more efficient
than EP to achieve in vivo transfection in skin, was less inflammatory, and was as potent as EP to elicit
anti-N IgG responses (see Figure 4, D34). Needle-free jet delivery thus appears as a promising method
to deliver DNA vaccines in pigs. Interestingly, the anti-Env Ab response was also enhanced by the
prime-boost strategy, indicating that the Ab response to envelope determinants was promoted by the
DNA prime. Such priming could have been induced by the GP4GP5M chimera, which includes a
highly variable linear neutralizing epitope [22], or by the different PRRSV constructs through T helper
activation. We favor this latter hypothesis as we did not detect a benefit of DC-targeting with the
GP4GP5M chimera on anti-Env IgG responses, whereas it was obtained with the N antigen. However,
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the benefit of DC-targeting on the anti-N IgG response is less potent in the present study than in the
parallel study [9] where NPs were combined to DNA. Again, NPs may have had an adjuvant effect,
which has been shown to be necessary to obtain a positive effect of DC-targeting on the antibody and
especially on the T-cell responses in many instances [23,24]. NPs combination to DNA in PJ delivery
would need to be evaluated as the limited injection volume of the device may lead to precipitation of
DNA/NP complexes and the high-pressure delivery may lead to deformation of NPs. Other adjuvants,
less compelling than NPs, should be considered for DNA administration with PJ, either genetic or
pharmacologic adjuvants, such as plasmids encoding CD40 ligand or GM- CSF or resiquimod [25] or by
expression of RIG-I agonists produced during the DNA vaccine transcription process [26]. This positive
effect of the DNA-MLV prime-boost on the antibody response could be used for the generation of
protective antibody responses, ideally for cross-strain protection. However, epitopes involved in the
generation of broadly neutralizing antibodies have not yet been identified, but evidence supports their
existence [27].
Few works have evaluated the advantages of a DNA prime-boost to ameliorate PRRSV
vaccination. A DNA-inactivated PRRSV or recombinant adenovirus prime-boost improved the
anti-GP5 response in mice [28,29] but this approach has not been translated to pigs. The DNA-MLV
prime-boost with a plasmid encoding N or truncated N in pigs was shown to correct the negative
immunomodulatory properties of a PRRSV-2 MLV, by reducing the IL-10 and Treg responses generated
by MLV administration [30]. This strategy nevertheless did not improve the viral protection against
a heterologous challenge with a highly pathogenic strain [30]. We were not able to detect IL-10
production in our re-stimulation assays with overlapping peptides, possibly because a PRRSV-1 MLV,
such as MLV-FL13b, was not able to induce an immunomodulatory IL-10 response as a difference with
PRRSV-2 MLVs [31].
The priming with our DNA vaccines coding PRRSV-AG appeared to slightly reduce the increase
in body temperature detected at D2 post-heterologous challenge (D65) with FL07, especially in the PJ
groups. However, the rise in temperature induced by FL07 was very mild (1 ◦C) and clinical symptoms
were not detected in our Large White pigs. In the initial description of FL07 by one of us, the pathology
of FL07 was also limited [12]. In addition, the TCID50eq copy numbers/mL in blood was lower than
the ones in other studies with similar strains [32,33]. The relatively low viral load in FL07 may explain
the quite substantial, yet incomplete, cross-protection induced with MLV-FL13b alone which reduced
by at least five-fold the overall viremia. The efficacy of PRRSV MLV vaccines also depends greatly on
the degree of genetic similarity between the vaccine and challenge strains. A genomic analysis of the
ORF2-6 reveals that the amino acid homology between the MLV-FL13b and the challenge FL07 strains
was 84.9%, and 88% for GP5, what illustrates that the two strains were heterologous.
The immuno-potentiation achieved by the DNA-MLV prime-boost was not sufficient to improve
the incomplete cross-protection induced by MLV-only. Among hypotheses, it can be proposed
that CD8+ T-cell responses were not sufficiently elicited by our strategy and that CD8+ T-cells are
more instrumental to protection than CD4+ T-cells [34]. Indeed, the IFNγ T-cell ELISPOT assays
that we performed do not differentiate whether the responding cells are CD4+ and CD8+ T-cells,
and cytotoxicity may be a more important function than IFNγ synthesis. In addition, we may not
have used the best T-cell antigen(s) to achieve high cross-strain protection. NSP5, which appears as a
major immuno-dominant and well conserved T-cell antigen across PRRSV strains, would have been an
interesting candidate [35]. However, because we wished to evaluate the targeting of T-cell antigens to
DCs, we excluded NSP5 which contains many transmembrane domains and is thus not compatible
with expression in VBs. Finally, an optimal cross-protection may require the contribution of broadly
NAbs [27], which we could not detect to be induced by our strategy (see below).
We were not able to identify the immune parameters associated with the partial heterologous
protection induced by MLV-FL13b. Either we are missing pertinent parameters such as the CD8+
T-cell response, or protection could be controlled by the combination of immune parameters, possibly
independently of their magnitude. It remains possible that the timing of the immune parameter
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measurement, especially the T-cell response, may have affected the correlation study. Indeed,
we measured the IFNγ T-cell response 15 days after the boost, in order to compare the results with
our previous work [9] and also because this timing was identified as an optimal time-point in another
DNA-MLV prime-boost study [36]. We also measured the T-cell response after the challenge, but the
spontaneous IFNγ responses were very high and impeded any interpretation. Finally, we found that
a partial heterologous protection was achieved in the absence of detectable NAbs at the challenge
time-point. PRRSV has often been reported to induce very low NAb titers which appear late in
infection [37,38] or which were even non-detectable upon infection or MLV administration in several
cases [39–44]. The non-detection could be due to the currently used in vitro techniques which may not
capture the neutralization of the virus occurring in vivo. We used the classical MARC-145 cell-based
NAb assay, which involves a simian kidney cell line that does not express the porcine CD169 and
CD163 PRRSV receptors. Therefore, it is possible that the differences in receptor engagement between
the in vitro assay and the in vivo situation is associated with the lack of NAb detection, as proposed in
the case of flaviviruses [45]. Finally, porcine macrophage-based assays are difficult to parametrize,
and cannot be used in the case of MLV-13b which does not grow in these cells. Research efforts are
urgently needed to further develop system vaccinology tools, in particular, functional and refined
biochemical antibody assays, to improve our understanding of the parameters involved in PRRSV
control in order to develop the next generation of PRRSV vaccines as well as vaccines against other
pig diseases.
Our study reveals that a DNA-MLV prime boost strategy holds promises for the control of PRRSV
in pigs and it opens the way for further developments. The delivery with PJ allows a good transfection
but minimal inflammation suggesting that it should be combined with complementary adjuvants.
The effect of other T-cell antigens, such as the conserved NSP5 T-cell antigen, should also be evaluated.
Finally, although much further down the road, broadly neutralizing epitopes, which appear to exist
but remain to be molecularly identified [27], could be expressed in DNA vaccines associated with an
MLV boost including shuﬄed structural genes [46].
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